This company listing is no longer active
RDUS Stock Overview
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Radius Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$4.97 |
| Beta | 0.52 |
| 1 Month Change | -0.39% |
| 3 Month Change | 78.76% |
| 1 Year Change | -27.08% |
| 3 Year Change | -55.21% |
| 5 Year Change | -71.49% |
| Change since IPO | 26.09% |
Recent News & Updates
Recent updates
Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Shareholder Returns
| RDUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | -4.7% | -3.7% |
| 1Y | -27.1% | -2.7% | 20.2% |
Return vs Industry: RDUS underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: RDUS underperformed the US Market which returned -11.6% over the past year.
Price Volatility
| RDUS volatility | |
|---|---|
| RDUS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDUS's share price has been volatile over the past 3 months.
Volatility Over Time: RDUS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 293 | G. Martin | radiuspharm.com |
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.
Radius Health, Inc. Fundamentals Summary
| RDUS fundamental statistics | |
|---|---|
| Market cap | US$480.77m |
| Earnings (TTM) | -US$68.63m |
| Revenue (TTM) | US$223.36m |
2.2x
P/S Ratio-7.0x
P/E RatioIs RDUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDUS income statement (TTM) | |
|---|---|
| Revenue | US$223.36m |
| Cost of Revenue | US$19.47m |
| Gross Profit | US$203.89m |
| Other Expenses | US$272.52m |
| Earnings | -US$68.63m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 91.28% |
| Net Profit Margin | -30.72% |
| Debt/Equity Ratio | -124.2% |
How did RDUS perform over the long term?
See historical performance and comparison